We are live on ! Find out more

Ionis Pharmaceuticals

IONS

Market cap $10.1B

61.05 USD

-1.38

2.21%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

61.05

0.00

0%

1 day

-2.21%

5 days

0.84%

1 month

10.4%

3 months

-21.05%

6 months

-25.51%

Year to date

-23.37%

1 year

43.24%

5 years

55.98%

10 years

101.35%

About: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Employees: 1,402

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 15.3%

Neutral 64.4%

Negative 20.3%

Zacks Investment Research

Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?

The Motley Fool

Breakfast News: A Conversation With Ionis CEO

Biotech has been hot in 2026. The sector, tracked by the SPDR S&P Biotech ETF, (XBI +1.44%) is up 39% year to date -- beating tech and running even with energy.

Breakfast News: A Conversation With Ionis CEO

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31 in Munich. Presentations include one-year data from the open-label, long-term extension study of TRYNGOLZA® (olezarsen), recently approved in the U.S. as the first and only treatment for sHTG to reduce triglycerides and the risk o.

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026

The Motley Fool

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?

Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble in the earnings report.

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?

IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $IONS--IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law.

IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

The Motley Fool

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

20,000 shares were purchased for a total value of ~$1.1 million across multiple execution windows. The acquisition increased the director's total direct and indirect equity holdings by 34%.

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

Zacks Investment Research

IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook

Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.

IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

See News Rankings

Price charts implemented using Lightweight Charts™